26.35
-0.25 (-0.94%)
| Previous Close | 26.60 |
| Volume | 481,690 |
| Price / Earnings (Forward) | 6.75 |
| Price / Sales | 1.51 |
| Price / Book | 1.58 |
| 52 Weeks Range |
| Profit Margin | -14.76% |
| Operating Margin (TTM) | 4.63% |
| Diluted EPS (TTM) | -2.24 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | -46.40% |
| Total Debt/Equity (MRQ) | 79.70% |
| Current Ratio (MRQ) | 2.41 |
| Operating Cash Flow (TTM) | 175.75 M |
| Levered Free Cash Flow (TTM) | 144.75 M |
| Return on Assets (TTM) | 3.56% |
| Return on Equity (TTM) | -12.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Pacira BioSciences, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -1.19 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.79% |
| % Held by Institutions | 110.89% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |